- Bloomberg•4 hours ago
Joe Jimenez, Novartis chief executive officer, discusses the outlook for the pharmaceutical industry under President Donald Trump. He speaks with Bloomberg's Erik Schatzker at the World Economic Forum ...
- TheStreet.com•2 days ago
Drugmaker faced antitrust charges over 2013 Synacthen purchase.
- MarketWatch•2 days ago
Novartis CEO Joseph Jimenez spoke to WSJ's Deborah Ball about the impact that a Trump presidency could have on the pharmaceutical industry.
NVS : Summary for Novartis AG Common Stock - Yahoo Finance
Novartis AG (NVS)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||70.23 - 70.88|
|52 Week Range||66.93 - 83.58|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||24.83|
|Dividend & Yield||2.72 (3.78%)|
|1y Target Est||N/A|